Press Release: Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Novartis International AG / Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely …

Novartis International AG / Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS. Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely ...

Press Release: Phase III data in The Lancet show -2-

such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical …

such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical ...

Neuer Finanzminister Olaf Scholz: „Die Null muss stehen!“

von Martin Blümel, €uro am Sonntag

Die Neuauflage der GroKo unter Angela Merkel ist besiegelt, der 177-seitige Koalitionsvertrag unterschrieben. Damit ist die längste Regierungsbildung in der Geschichte …

von Martin Blümel, €uro am Sonntag

Die Neuauflage der GroKo unter Angela Merkel ist besiegelt, der 177-seitige Koalitionsvertrag unterschrieben. Damit ist die längste Regierungsbildung in der Geschichte ...